Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple supplement tame inflammation before cancer surgery?

NCT ID NCT07675421

Disease control Sponsor: Federal University of Minas Gerais Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether a dietary supplement called HMB (beta-hydroxy-beta-methylbutyrate) can lower inflammation and improve recovery in people with head and neck cancer who are about to have surgery. Participants take either HMB or a placebo daily for 30 days before their operation. Researchers measure inflammatory markers in the blood and track muscle strength and postoperative outcomes to see if HMB makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beta-hydroxy-beta-methylbutyrate (HMB)
What this could lead to
If HMB reduces inflammation and improves muscle strength before surgery, it could help head and neck cancer patients recover better after tumor removal.
What could go wrong
This is a small, early-stage trial with only 66 participants, so results may not apply to all patients. HMB is a supplement and may not produce significant clinical benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals aged 18 years or older; * Both sexes (male and female); * Patients treated at the outpatient clinic for head and neck carcinoma; * Indication for potentially curative tumor resection surgery. Exclusion Criteria: * Diagnosis of cancer of the face, skin, paranasal sinuses, or thyroid; * Undergoing neoadjuvant or palliative treatment; * Cognitive or intellectual impairment that may hinder proper understanding of the study; * Refusal to participate or to sign the informed consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer head and neck carcinoma Head and Neck Neoplasms Inflammation Postoperative Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • School of Medicine, Federal University of Minas Gerais

    RECRUITING

    Belo Horizonte, Minas Gerais, 30130-100, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.